Researchers found that 61 percent of patients they analyzed carried germline pathogenic or likely pathogenic variants in candidate cancer predisposition genes.
The researchers identified rare germline loss-of-function variants across the ELP1 gene in 14 percent of pediatric patients in a medulloblastoma subgroup.
The study suggested that ALL glucocorticoid resistance stemming from alterations that drive down CELSR2 levels might be combated with the BCL2-targeting drug venetoclax.
Researchers demonstrated the importance of integrating mutational and transcriptomic profiles to improve understanding of AML and MDS patients' prognosis.
Direct-to-consumer genetic testing companies are searching for a genetic reason for why some people, but not others, become gravely ill with COVID-19, the Detroit Free Press reports.
In PNAS this week: forward genetics-base analysis of retinal development, interactions of T cell receptors with neoantigens in colorectal cancer, and more.
